Cita APA

Riely, G., Ahn, M., Smit, E., Ramalingam, S., Tsao, A., & Felip Font, E. (2022). Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: Phase II PHAROS study design.

Citación estilo Chicago

Riely, Gregory, Myung-Ju Ahn, Egbert Smit, Suresh Ramalingam, Anne Tsao, y Enriqueta Felip Font. Encorafenib Plus Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer: Phase II PHAROS Study Design. 2022.

Cita MLA

Riely, Gregory, et al. Encorafenib Plus Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer: Phase II PHAROS Study Design. 2022.